The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles

Gene Therapy
T KottkeR Vile

Abstract

We have reported that retroviral particles adhered to the surface of antigen-specific T cells can be carried to metastases following adoptive transfer in vivo, a process we have called viral hitch hiking. Following antigen-driven T-cell accumulation at tumors, viral particles productively infect tumor cells via envelope/receptor dependent interactions ('hand on' of virus from the T cell to the tumor cell). We describe here a second envelope/receptor independent pathway of viral hand on from T cells, dependent on T-cell activation. We show that the endosomolytic property of perforin promotes release of viral particles from endosomes into which they are co-delivered along with cytotoxic granules from the activated T cell. Therefore, hand on of MLV particles lacking any envelope can be used for in vivo delivery of vectors, where targeting is at the extremely specific level of recognition of antigen by the T-cell receptor, thereby dispensing with the need to engineer viral envelopes. These data reveal a novel pathway by which MLV viral particles exploit a functional immunological synapse and present new opportunities both to improve the efficacy of adoptive T-cell transfer and to target vectors for systemic gene delivery.

References

Mar 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·M J WagnerW C Summers
Aug 25, 1995·Cell·R A Weiss, C S Tailor
Jan 14, 1994·Cell·K A HogquistF R Carbone
Nov 10, 2000·Advanced Drug Delivery Reviews·K J HarringtonR G Vile
Mar 3, 2001·Current Opinion in Immunology·C YeeP D Greenberg
Jan 18, 2003·Immunity·Michael D BobardtPhilippe A Gallay
Feb 18, 2003·Science·Tadahiko IgakuraCharles R M Bangham
May 27, 2003·Nature Reviews. Immunology·Judy Lieberman
Sep 3, 2003·Nature Reviews. Cancer·Mark E Dudley, Steven A Rosenberg
Sep 23, 2003·Current Opinion in Immunology·Srikumar M RajaChristopher J Froelich
Jan 22, 2004·The Journal of Experimental Medicine·Clare JollyQuentin J Sattentau
Apr 29, 2004·Journal of Virology·Andrey A Kolokoltsov, Robert A Davey
Aug 10, 2004·Nature Biotechnology·Gregory A DanielsRichard G Vile
Sep 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Steven A Rosenberg, Mark E Dudley
Sep 24, 2004·Gene Therapy·U BlömerU Martin
Dec 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Douglas C PalmerNicholas P Restifo

❮ Previous
Next ❯

Citations

Oct 2, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Timothy KottkeRichard G Vile
Aug 20, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Candice WillmonRichard Vile
Jan 19, 2008·Cancer Gene Therapy·L KrügerJ A Kleinschmidt
Aug 28, 2007·The Journal of Gene Medicine·Susanne I LangRichard G Vile
Sep 14, 2020·Cancer Gene Therapy·Sadia ZafarAkseli Hemminki
Jun 13, 2020·Frontiers in Cell and Developmental Biology·Christos DogrammatzisMaria Kalamvoki
Jan 11, 2007·Cancer Research·Uma ThanarajasingamRichard G Vile

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.